Tumor immunotherapy, especially T cell based therapy, is becoming the main force in
clinical tumor therapies. Bispecific T cell engager (BiTE) uses the single chain variable …

Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that
redirect T cells to tumor surface antigens. While efficacious against certain hematological …

Oncolytic viruses (OVs) are potent anti-cancer biologics with a bright future, having
substantial evidence of efficacy in patients with cancer. Bi-and tri-specific antibodies …

Bispecific T‐cell engagers (BiTEs) are a new class of immunotherapeutic molecules
intended for the treatment of cancer. These molecules enhance the patient's immune …

Immuno‐oncology therapies engage the immune system to treat cancer. BiTE (bispecific T‐
cell engager) technology is a targeted immuno‐oncology platform that connects patients' …

Oncolytic viruses (OVs) are novel anticancer agents that combine direct cancer cell killing
with the stimulation of antitumor immunity. In addition, OVs can be engineered to deliver …

Bispecific T-cell engager antibodies (BiTE) have been explored as a means to recruit
cytolytic T cells to kill tumor cells. The transferrin receptor (TfR) is highly expressed on the …

A novel bispecific T-cell engager (BiTE) has been developed as an efficient
immunotherapeutic molecule specifically bringing the T-cell and the tumor target together for …

There is increasing evidence that T cells are able to control tumor growth and survival in
cancer patients, both in early and late stages of the disease. However, tumor-specific T-cell …

As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising
antibody therapy for various kinds of cancer. In general, T-BsAbs have dual-binding …